InsidersTradesSigma
申报总数
公司
▲ 买入（3 笔）
▼ 卖出（0 笔）
内部人交易记录
高级管理人员已披露买入
3
已披露卖出
0
T+90 胜率
0%
T+90 平均收益
-5.6%
基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
Discover the full record of transactions filed by olivier Charmeil, 独立董事. Officer active across 2 companies, notably GENOWAY. Cumulatively, 6 filings have been recorded. Split: 3 buys · 0 sell. Total volume traded: €413k. History available since 4 May 2023. The latest transaction was disclosed on 20 August 2026 (Acquisition). Regulator: AMF. All data is openly available.
Companies and markets linked to olivier Charmeil
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报6 总计
1,505.754 股@ €77.56180.0001% mcap100.0% 占其流量Parts de fonds d'épargne salarialeHors plateforme de négociationISIN QS00040862682026DD1135503
标准退出：2026年11月18日 (T+90)
55,000 股0ActionHors plateforme de négociationISIN FR00001205782026DD1125509
7,000 股0ActionHors plateforme de négociationISIN FR00001205782026DD1123406
21,145 股0ActionHors plateforme de négociationISIN FR00001205782026DD1116396
标准退出：2026年8月23日 (T+90)
42,553 股@ €2.3525.3% 占其流量ActionHors plateforme de négociationISIN FR00040535102025DD1085526
80,000 股@ €3.7074.7% 占其流量ActionHors plateforme de négociationISIN FR00040535102023DD899714
标准退出：2023年8月2日 (T+90)
6 条申报中的 6 条
About olivier Charmeil
olivier Charmeil is Administrateur indépendant de genOway et Executive Vice President, General Medicines chez Sanofi. He has 5 filings in total, and across the 5 sampled recent filings, buy transactions total 396000 EUR and sell transactions total 0 EUR, with dates ranging from 2023-05-12 to 2026-07-07. The companies mentioned are SANOFI and GENOWAY, and the most frequent transaction nature is Mainlevée de nantissement.
